The prediction using diffusion-weighted MRI of the response evaluation in unresectable pancreatic cancer in patients undergoing neoadjuvant therapy. A pilot study

Not Applicable

• Conditions: Pancreatic carcinoma

• Registration Number: JPRN-UMIN000028030
• Lead Sponsor: Wakayama Medical University

Brief Summary

Pre/post-treatment whole tumor ADC value correlated with tumor cell destruction rate among all parameters (R=0.630/0.714, P<0.001/<0.0001). The post-treatment cutoff value of vascular abut site ADC for discriminating between grade<IIb and >=grade IIb was determined as 1.42x10-3 mm2/s and predicts R0 curability. For histological response, the post-treatment whole tumor ADC cutoff value for discriminating between grade<IIb and >= grade IIb was determined as 1.40x10-3 mm2/s.

Detailed Description

Not available

Study Timeline

• Study Start: 2017-07-10
• Results First Posted: 2020-02-01
• Study Completion: 2020-07-31
• Last Update Posted: 20 November 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 28

Inclusion Criteria

Not provided

Exclusion Criteria

1. Without severe drug allergy. 2. With history of malignant disease within 5 years. 3. Active stutus of infectious disease. 4. With metal in body which is contraindication for MRI. 5. With claustrophobia. 6. Incapability to collaborate in respiration. 7. The presence of uncontrollable ascites. 8. The presence of uncontrollable DM 9. The presence of uncontrollable CHD, angina, HTN, and arrhythmia. 10. The presence of severe neurological, psychological disease or their history.

Study & Design

• Study Type: Observational
• Study Design: Not specified